Sleep medicine pharmacotherapeutics overview: Today, tomorrow, and the future (Part 2: Hypersomnia, parasomnia, and movement disorders)

Seema Gulyani; Rachel E. Salas; Charlene E. Gamaldo

doi:10.1378/chest.12-0561

Sleep medicine pharmacotherapeutics overview: Today, tomorrow, and the future (Part 2: Hypersomnia, parasomnia, and movement disorders)

Seema Gulyani, Rachel E. Salas, Charlene E. Gamaldo

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Over the past 10 years, significant strides have been made in therapeutics for sleep disorders. In this second installment of a two-part review series, we discuss the current evidence surrounding the mechanisms of actions, indications, efficacy, and adverse side effects associated with the current over-the-counter and pharmacotherapeutics for hypersomnia, parasomnias, and movement disorders of sleep.

Original language	English (US)
Pages (from-to)	242-251
Number of pages	10
Journal	CHEST
Volume	143
Issue number	1
DOIs	https://doi.org/10.1378/chest.12-0561
State	Published - Jan 2013

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine
Critical Care and Intensive Care Medicine
Cardiology and Cardiovascular Medicine

Access to Document

10.1378/chest.12-0561

Fingerprint Dive into the research topics of 'Sleep medicine pharmacotherapeutics overview: Today, tomorrow, and the future (Part 2: Hypersomnia, parasomnia, and movement disorders)'. Together they form a unique fingerprint.

Cite this

@article{52d840e0f123458daa9e9a7f81b851f0,

title = "Sleep medicine pharmacotherapeutics overview: Today, tomorrow, and the future (Part 2: Hypersomnia, parasomnia, and movement disorders)",

abstract = "Over the past 10 years, significant strides have been made in therapeutics for sleep disorders. In this second installment of a two-part review series, we discuss the current evidence surrounding the mechanisms of actions, indications, efficacy, and adverse side effects associated with the current over-the-counter and pharmacotherapeutics for hypersomnia, parasomnias, and movement disorders of sleep.",

author = "Seema Gulyani and Salas, {Rachel E.} and Gamaldo, {Charlene E.}",

year = "2013",

month = jan,

doi = "10.1378/chest.12-0561",

language = "English (US)",

volume = "143",

pages = "242--251",

journal = "Chest",

issn = "0012-3692",

publisher = "American College of Chest Physicians",

number = "1",

}

TY - JOUR

T1 - Sleep medicine pharmacotherapeutics overview

T2 - Today, tomorrow, and the future (Part 2: Hypersomnia, parasomnia, and movement disorders)

AU - Gulyani, Seema

AU - Salas, Rachel E.

AU - Gamaldo, Charlene E.

PY - 2013/1

Y1 - 2013/1

N2 - Over the past 10 years, significant strides have been made in therapeutics for sleep disorders. In this second installment of a two-part review series, we discuss the current evidence surrounding the mechanisms of actions, indications, efficacy, and adverse side effects associated with the current over-the-counter and pharmacotherapeutics for hypersomnia, parasomnias, and movement disorders of sleep.

AB - Over the past 10 years, significant strides have been made in therapeutics for sleep disorders. In this second installment of a two-part review series, we discuss the current evidence surrounding the mechanisms of actions, indications, efficacy, and adverse side effects associated with the current over-the-counter and pharmacotherapeutics for hypersomnia, parasomnias, and movement disorders of sleep.

UR - http://www.scopus.com/inward/record.url?scp=84871964370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871964370&partnerID=8YFLogxK

U2 - 10.1378/chest.12-0561

DO - 10.1378/chest.12-0561

M3 - Article

C2 - 23276849

AN - SCOPUS:84871964370

VL - 143

SP - 242

EP - 251

JO - Chest

JF - Chest

SN - 0012-3692

IS - 1

ER -